Clinical Trial

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open, prospective, multi-center, single-arm phase II clinical study assessing the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin in patients with pMMR/MSS locally advanced middle and low rectal cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-21; most recent amendment 2025-03-27.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-03-27
Trial Details
NCT Number NCT06056804
Lead Sponsor Beijing Friendship Hospital
Collaborators: Peking Union Medical College Hospital
Conditions Locally Advanced Rectal Cancer
Enrollment 20 participants
Start Date 2024-01-03
Primary Completion 2024-12-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-02